<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR88211-0188 </DOCNO><DOCID>fr.2-11-88.f2.A1069</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF HEALTH AND HUMAN SERVICES</ITAG><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="41">[Docket No. 88N-0039]</ITAG><ITAG tagnum="52">Drug Export; `CONTAC' C Sustained Release Capsules</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingthat SmithKline Consumer Products has filed an application requesting approvalfor the export of the human drug `CONTAC' C Sustained Release Capsulesto Canada.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Relevant information on this application may be directedto the Dockets Management Branch (HFA-305), Food and Drug Administration,Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact personidentified below. Any future inquiries concerning the export of human drugsunder the Drug Export Amendments Act of 1986 should also be directed tothe contact person.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Rudolf Apodaca, Division of DrugLabeling Compliance (HFN-310), Center for Drug Evaluation and Research,Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8063.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>The Drug Export Amendments Act of 1986(Pub. L. 99-660) (section 802 of the Federal Food, Drug, and Cosmetic Act(the act) (21 U.S.C. 382)) provides that FDA may approve applications forthe export of drugs that are not currently approved in the United States.The approval process is governed by section 802(b) of the act. Section802(b)(3)(B) of the act sets forth the requirements that must be met inan application for approval. Section 802(b)(3)(C) of the act requires thatthe agency review the application within 30 days of its filing to determinewhether the requirements of section 802(b)(3)(B) have been satisfied. Section802(b)(3)(A) of the act requires that the agency publish a notice in the<T4>Federal Register </T4>within 10 days of the filing of an applicationfor export to facilitate public participation in its review of the application.To meet this requirement, the agency is providing notice that SmithKlineConsumer Products, One Franklin Plaza, P.O. Box 8082, Philadelphia, PA19101, has filed an application requesting approval for the export of thedrug `CONTAC' C Sustained Release Capsules to Canada. This product is indicatedin the use for symptomatic relief of colds, hay fever, and sinusitis. Theapplication was received and filed in the Center for Drug Evaluation andResearch on January 15, 1988, which shall be considered the filing datefor purposes of the act.Interested persons may submit relevant information on the application tothe Dockets Management Branch (address above) in two copies (except thatindividuals may submit single copies) and identified with the docket numberfound in brackets in the heading of this document. These submissions maybe seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Mondaythrough Friday.The agency encourages any person who submits relevant information on theapplication to do so by February 16, 1988, and to provide an additionalcopy of the submission directly to the contact person identified above,to facilitate consideration of the information during the 30-day reviewperiod.This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec.802, Pub. L. 99-660 (21 U.S.C. 382)) and under authority delegated to theCommissioner of Food and Drugs (21 CFR 5.10) and redelegated 21 CFR 5.44.<ITAG tagnum="21">Dated: January 25, 1988.</ITAG><ITAG tagnum="6">Sammie R. Young,</ITAG><ITAG tagnum="4">Acting Director, Office of Compliance, Center for Drug Evaluation andResearch.</ITAG><ITAG tagnum="40">[FR Doc. 88-2318 Filed 2-3-88; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></ITAG></TEXT></DOC>